DEFENCE THERAPEUTICS INC
Commented by Carsten Mainitz on March 14th, 2022 | 12:47 CET
BioNTech, Defence Therapeutics, MorphoSys - Shares with blockbuster potential!
Developing a blockbuster drug is the highest achievement in the pharmaceutical industry. A blockbuster is defined as a drug that can generate more than USD 1 billion in revenues per year. According to experts, the vaccine Comirnaty, developed by BioNTech and Pfizer, is likely to have brought in sales of well over USD 30 billion, thus clearly breaking the blockbuster barrier. Outside of vaccine research, there are also numerous companies with high long-term potential.
Read
Commented by Armin Schulz on March 7th, 2022 | 13:05 CET
Valneva, Defence Therapeutics, MorphoSys - Blockbuster potential
Every pharmaceutical or biotech company wants a blockbuster. This term refers to a drug that generates annual sales of at least USD 1 billion. The best-known blockbuster drug currently is the Corona vaccine from BioNTech. In 2020, the rheumatism drug Humira was in the top spot with sales of over USD 20 billion. The Mainz-based vaccine manufacturer is likely to have significantly surpassed this mark in 2021. If a company hits the big time, it can reap the rewards for 20 years before the patent expires. Today, we take a look at three companies that have potential blockbusters.
Read
Commented by Stefan Feulner on March 4th, 2022 | 13:33 CET
Bayer, Defence Therapeutics, Merck KGaA - At the start of the trend
The biotech industry is the innovative engine for a pharmaceutical industry dependent on new concepts due to the shift from blockbuster products to personalized medicine. Even before Corona, more than EUR seven billion per year was invested in R&D in 2019. The development of new drugs is particularly important for the pharmaceutical industry, as patent protection for many blockbuster drugs is expiring or has already expired. For this reason, the pharmaceutical industry is now much more often entering biotech companies in the early development phases of a new drug. The example of vaccine manufacturers has successfully highlighted this strategy, which will also be applied to other diseases in the future.
Read
Commented by André Will-Laudien on February 9th, 2022 | 12:22 CET
MorphoSys, Defence Therapeutics, Valneva, CureVac - Find the bio blockbuster!
The biotech sector is a highly dynamic growth market within the equity universe. It is characterized by investment volumes of unprecedented size, which is also the reason for the high innovation rate characteristic of the sector. Price reactions to positive or negative surprises can be very volatile, and these tendencies are often exacerbated by the intervention of stop orders or the occurrence of derivative slippage. Vaccine manufacturers were down over 50% across the board, as the pandemic is being traded as a phase-out. The vaccination rate does not appear to be increasing significantly. Where are the opportunities for investors at the moment?
Read
Commented by Armin Schulz on January 31st, 2022 | 13:31 CET
BioNTech, Defence Therapeutics, Mainz Biomed - After Corona, cancer is the next hype
The euphoria surrounding vaccine manufacturers has come to an end. The majority of investors believe that the end of the pandemic is near with Omicron. More and more states are abandoning restrictions and slowly returning to normalcy. If that happens, one of the biggest hypes of the last decade will come to an end. The pharmaceutical and biotech industries have earned very well from it. After the hype is before the hype. The next big story is cancer, and there are more and more cancer cases, so fighting the disease is a lucrative business. A lot is happening in this area, so we are looking at three companies today.
Read
Commented by Nico Popp on January 25th, 2022 | 10:15 CET
BioNTech, Defence Therapeutics, Nordex: Investors must pay attention here!
"Defying cancer" was the headline of the Frankfurter Allgemeine Zeitung a few days ago. The interview was illustrated with the two leading BioNTech heads, Özlem Türeci and Uğur Şahin. The famous German scientists' statement revolved around further projects for BioNTech and the fight against cancer. At the same time, BioNTech's stock, like many other pandemic winners, dropped. What does this mean for investors now?
Read
Commented by Carsten Mainitz on January 20th, 2022 | 12:14 CET
Evotec, Defence Therapeutics, Formycon - Who will benefit from Omicron?
The Coronavirus has shown that without biotechnology and ongoing research, we are relatively defenseless against the whims of nature. What would have happened if novel technology had not been available to produce potent vaccines in a very short time? Would our intensive care units have been as crowded as they were in Italy at the beginning of the pandemic? Would hospital triage be the norm today? No one can say for sure, but history has shown how epidemics - such as the Spanish flu - have claimed many lives in the past.
Read
Commented by Stefan Feulner on January 14th, 2022 | 11:44 CET
BioNTech, Defence Therapeutics, PAION - Seizing the momentum
The Corona pandemic brought biotechnology to the forefront of society's consciousness, especially since the first vaccines were created in German laboratories. However, the biotech spectrum is much broader than pandemic vaccine research. In addition to research in medicine, the sector is playing an increasingly important role in environmental protection, agriculture and the ongoing climate change.
Read
Commented by André Will-Laudien on December 28th, 2021 | 07:15 CET
BioNTech, Pfizer, Defence Therapeutics, Valneva - The Corona year 2022 is coming
The German government has moved its goal of vaccinating 80% of the population against the coronavirus at least once into the new year. The targeted quota is now to be achieved by the end of January, a government spokesman told the press. The background is that only 73.4% of the population has been vaccinated so far, and the missing 5.3 million first-time vaccinations could hardly be achieved by January 7. The interim goal of 30 million vaccinations by the end of the year, on the other hand, will most likely be met after Christmas, government sources say. The general vaccination obligation is to come on the agenda of the Federal Parliament in the first meeting week in the new year. Thus also the year 2022 will stand under the star "Corona". The following shares are part of the orchestra.
Read
Commented by Carsten Mainitz on December 8th, 2021 | 12:53 CET
Pfizer, Defence Therapeutics, Novavax - Who will benefit from Omicron?
The world is trembling before the new Corona variant Omicron. Stock exchanges are going down, panic reigns in the crypto markets and politicians are outbidding each other with calls for tighter lockdown regulations. However, some experienced epidemiologists already see the emergence of Omicron as an indication of an imminent change from pandemic to endemic, in which we will live with the Coronavirus as if it were the flu. However, everyone agrees on one thing: we will still need vaccination. Who is this good news for?
Read